Letter to the Editor

Inorganic Nitrate for Blood Pressure Lowering?

To the Editor:

Kapil et al. reported that potassium nitrate ingestion lowers blood pressure (BP) in human subjects. Peak plasma nitrate (NO$_3^-$) and nitrite (NO$_2^-$) concentrations increased up to 35- and 4-fold, respectively. Increased plasma cGMP levels suggest that the depressor action of nitrate is mediated by the NO/cGMP cascade, presumably after reduction of NO$_3^-$ to NO$_2^-$ and its reduction to NO. Using $^{15}$NO$_3^-$, we provided evidence for $^{15}$NO$_3^-$ to $^{15}$NO$_2^-$ reduction in humans. Similar results were obtained for $^{15}$NO$_3^-$ and S-$^{15}$nitroso-N-acetylcysteine ethyl ester in male rabbits (Figure). Oral administration of isosorbide dinitrate (ISDN) (0.13 mmol daily) and pentaerythrityl tetranitrate (PETN) (0.25 mmol daily) increased moderately plasma concentration of NO$_3^-$ (1.2- and 1.4-fold, respectively) and NO$_2^-$ (2.2- and 1.8-fold, respectively) in young subjects.

Inorganic nitrates (R-ONO$_2$), inorganic salts of NO$_3^-$, and thionitrites (R-SNO) seem to lower BP through similar mechanisms, but their pharmacokinetics and pharmacodynamics differ considerably. The single dose of 0.32 to 0.45 mmol NO$_3^-$/kg is up to 60 times the mean daily endogenous NO synthesis rate in healthy subjects and up to 36 times the therapeutic ISDN and PETN dose. NO$_3^-$ required for BP lowering results in very high and long-lasting extracellular and intracellular NO$_3^-$ and NO$_2^-$ concentrations, which may, in turn, exert toxic, mutagenic, and carcinogenic effects. NO$_3^-$ and NO$_2^-$ are actively transported in various cells including the nephron. High millimolar tissue concentrations of NO$_3^-$ may induce acidosis in mammalian cells. Also, elevation of methemoglobin, oxidative stress, and glutathione consumption may ensue.

Ingestion of NO$_3^-$-rich foods or cheap NO$_3^-$ salts for NO-mediated BP lowering is tempting. However, ingestion of large NO$_3^-$ amounts carries serious risks because of the unpredictable harmful potential of the NO$_3^-$/NO$_2^-$/NO/NH$_3$ system. Before NO$_3^-$ supplementation can be applied clinically for BP lowering, efficacy and safety needs to be demonstrated in large clinical trials.

Figure. A–C, Pharmacokinetics of orally administered $^{15}$NO$_3^-$ (A), $^{15}$NO$_2^-$ (B), and S-$^{15}$nitroso-N-acetylcysteine ethyl ester ($^{15}$NACET) (C) to rabbits. D, BP effect of intravenous $^{15}$NACET in a rabbit. Data are mean±SD from duplicate analyses (A and B) in one rabbit each or from three rabbits (C).

(Hypertension. 2011;57:e1-e2.)

© 2011 American Heart Association, Inc.

Hypertension is available at http://hyper.ahajournals.org

DOI: 10.1161/HYPERTENSIONAHA.110.164574
studies. However, these trials cannot exclude an increased $\text{NO}_3^-/\text{NO}_2^-$-induced cancer risk.

Disclosures

None.

Dimitrios Tsikas  
Dirk O. Stichtenoth  
Jens Jordan 

Institute of Clinical Pharmacology  
Hannover Medical School  
Hannover, Germany


Inorganic Nitrate for Blood Pressure Lowering?
Dimitrios Tsikas, Dirk O. Stichtenoth and Jens Jordan

Hypertension. 2011;57:e1-e2; originally published online December 6, 2010;
doi: 10.1161/HYPERTENSIONAHA.110.164574

Hypertension is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 2010 American Heart Association, Inc. All rights reserved.
Print ISSN: 0194-911X. Online ISSN: 1524-4563

The online version of this article, along with updated information and services, is located on the
World Wide Web at:
http://hyper.ahajournals.org/content/57/2/e1

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in Hypertension can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to Hypertension is online at:
http://hyper.ahajournals.org//subscriptions/